Alizé Pharma is a group of privately held biopharmaceutical companies specialized in the development of innovative biopharmaceutical drugs, proteins and peptides, for the treatment of metabolic diseases and cancer.

The first entity of the Group, Alizé Pharma SAS, is focused on the AZP-01 program, a peptide derived from unacylated ghrelin, currently at the preclinical stage of development for the treatment of Type II diabetes and other metabolic and cardiovascular indications.

The second company, Alizé Pharma II SAS, is dedicated to the development of ASPAREC® (AZP-02), a new PEGylated recombinant L-asparaginase for the treatment of acute lymphoblastic leukemia, and currently in Phase I clinical development.